Gilead Sciences, Inc.
GILD
$114.43
-$2.78-2.37%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.40% | 7.02% | 5.36% | 5.26% | -3.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.40% | 7.02% | 5.36% | 5.26% | -3.72% |
| Cost of Revenue | -1.86% | 0.58% | 7.07% | 10.78% | 15.40% |
| Gross Profit | 8.81% | 8.86% | 4.89% | 3.70% | -8.18% |
| SG&A Expenses | 17.78% | 7.22% | -25.96% | 3.26% | -21.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.28% | 1.01% | -9.15% | 5.13% | -7.35% |
| Operating Income | 1.01% | 16.61% | 41.02% | 5.50% | 3.90% |
| Income Before Tax | 31.08% | -58.76% | 29.22% | -445.00% | -18.56% |
| Income Tax Expenses | 62.45% | -303.42% | -20.22% | -199.68% | -40.45% |
| Earnings from Continuing Operations | 25.83% | -42.31% | 55.34% | -523.78% | -13.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 71.43% |
| Net Income | 24.77% | -42.52% | 54.45% | -512.87% | -12.87% |
| EBIT | 1.01% | 16.61% | 41.02% | 5.50% | 3.90% |
| EBITDA | 0.95% | 13.45% | 30.73% | 6.02% | 8.69% |
| EPS Basic | 24.78% | -42.48% | 54.69% | -513.20% | -12.59% |
| Normalized Basic EPS | -0.22% | 14.92% | 40.87% | 3.81% | 6.20% |
| EPS Diluted | 24.78% | -42.20% | 55.42% | -518.00% | -13.13% |
| Normalized Diluted EPS | -0.46% | 15.10% | 41.42% | 4.90% | 6.53% |
| Average Basic Shares Outstanding | 0.00% | -0.08% | -0.16% | -0.08% | -0.32% |
| Average Diluted Shares Outstanding | 0.24% | -0.24% | -0.56% | -1.11% | -0.63% |
| Dividend Per Share | 2.67% | 2.67% | 2.67% | 2.67% | 2.74% |
| Payout Ratio | -0.17% | 0.79% | -0.33% | -1.25% | 0.18% |
